TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of patients with Medicare-billed health assessments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative neurological deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative partial thromboplastin time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite primary outcome of cardiovascular death, stroke, or hospitalization for worsening of heart failure or for acute coronary syndrome
Endpoint domain: Mortality/survival
Primary endpoint: Primary safety outcome of death, stroke, or serious adverse events related to rhythm control therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Molluscum contagiosum lesion count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant-reported improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Investigator-reported improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of undernutrition among pregnant women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak oxygen uptake (Peak Vo2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased concussion knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: velocity and stride length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with a decrease of at least 2 points in the SAF‐A score without worsening of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: problem-solving impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disability at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total cortisol metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 11β‐HSD2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adherence to guidelines for antibiotic treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean post-intervention scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: pain severity at rest on the first postoperative day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-year primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ctDNA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of conjunctivitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of PEP prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Movement slowness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Altered movement rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean score of hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of allopurinol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution of allopurinol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined concentration at half-maximal XO inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SEE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of visual hallucinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of recurrent ischemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Ever screened for HBV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fully vaccinated against HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean DIAGNOdent numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of white spot lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge and understanding of low-risk drinking guidelines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in 6MWD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TTRRosendaal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for avoiding moderate anxiety or depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of participants achieving normal ESS scores (≤ 10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving a ≥ 25% decrease from baseline in ESS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AHRS scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basic health knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Downregulation of neuroinflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DAS28‐ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAQ‐DI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: children's behavior rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: walking distance measured by the 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blockage or obstruction of graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: onset of grade 1 reaction
Endpoint domain: Adverse events/effects
Primary endpoint: progression of radiation dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the receiver operator characteristic curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSTS93 function scoring
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time saved from LPG use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Increased time for household chores and leisure activities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Increased number of meals cooked per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced time spent gambling
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Mean change in WSRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAIS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inflammatory markers (WBCs, hsCRP, IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dialysis adequacy assessed by URR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in the number of DRPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale/score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total incidence of adverse reactions in postanaesthesia care unit
Endpoint domain: Adverse events/effects
Primary endpoint: Children's awareness and understanding of trial processes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Length growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head circumference growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of TNSS, TNNSS and RQLQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TCONS_00483150 as a diagnostic biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced scores for depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less suicidal ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Effect of TIME on staff experience
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: MACCE rate at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Presenteeism costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Probability of financial savings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: P-ESES score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FBG levels decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2hPG levels decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of respondents reporting ≥150 weekly minutes of MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean minutes of weekly MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV and STI testing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tramadol dosage 24 hours after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical rating scale (NRS) scores for pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional Regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CV death, MI, or severe recurrent ischemia (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: PROMIS Pain Interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Self-Efficacy Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hsTnT changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NT-proBNP changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GDF-15 changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional status improvement (New York Heart Association class)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Echocardiographic parameters improvement (ejection fraction, end-diastolic diameter, end-systolic diameter, mitral regurgitation severity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QRFT measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QVIT measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inadequacy in protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: WOMAC function and total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opsonophagocytic activity geometric mean fold rises (GMFRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Full-length S-binding IgG GMFRs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutralizing titres against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: weekly smoking behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evaluations of smoking stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: IEF change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FI-burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Salt iodization levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: debriefing experiences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: students' stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impressions of VAD facilitators' practices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean number of heavy drinking days (HDDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of unscheduled bleeding days and spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle circumference reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epifascial thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on required abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of treatment sensitivity (TS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of treatment sensitivity (TS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year CLTI-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Diversity of glycophorin genes responsible for Sta antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in intestinal flora diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-last of oral hydromorphone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-last of intravenous hydromorphone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of oral hydromorphone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in low-contrast visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic nonunion
Endpoint domain: Adverse events/effects
Primary endpoint: GHSI total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occlusal Time (OT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disocclusion Time (DT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymmetry Index of Occlusal Force (AOF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of reaching baseline seizure count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: total cognition score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Exacerbations within 14 days of ICS step-down
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early discontinuation of endocrine therapy (ET)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy for nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health promoting behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat STI diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: TP rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-wave normalisation and U-wave disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of increase in blood potassium concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Self-Rating Anxiety Scale (SAS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Rating Depression Scale (SDS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of knees with alignment within 3° of neutral
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Primary Composite Endpoint (PCE)
Endpoint domain: Mortality/survival
Primary endpoint: 30-day renal function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 12-month death or myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: 12-month hospitalization cost
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Decrease of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Range of motion (ROM) of the knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: FM-B scale and BBS scale scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cyclic fatigue resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttraumatic Stress Disorder Checklist-5 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-SWL pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of miR‐27a, miR‐218 and miR‐21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: 3- and 6-month confirmed disability progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial FMD area AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postprandial MVBF AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: baseline tissue oxygen saturation (StO2%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper-limb dexterity functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forearm supination motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral narcotic use in the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived threat severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: susceptibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Allocation recommendations for advanced therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for airway maneuvers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in primary seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Operative Performance Rating Scale Overall Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Response control in food stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibitory control deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction times based on food type
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menopause-related symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Couple relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from baseline in pupil diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in minute ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major adverse cerebral and cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Interobserver agreement on CVM staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Well controlled GERD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic remission status on the PSWQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment response on the PSWQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Max cycles to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Max load prior to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: slower linear (length) velocity growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: later WFL growth timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ESSPRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRESS responders at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor function of the tibialis anterior muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes